A practical reference on circadian rhythm: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-11-10 and is reviewed periodically as new material appears.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
This bonding mode is observed in the commonly available metal carbonyls: Co2(CO)8, Fe2(CO)9, Fe3(CO)12, and Co4(CO)12. In certain higher nuclearity clusters, CO bridges between three or even four metals. These ligands are denoted μ3-CO and μ4-CO. Less common are bonding modes in which both C and O bond to the metal, such as μ3η2.
=== Subsidiaries === 2GO Express, Inc. – Provides land, air, and sea transportation including courier services, general cargo, sea cargo services, and last-mile delivery for e-commerce. It operates a nationwide network of retail outlets and partner agents and partners with FedEx for international express services. 2GO Logistics, Inc. – Provides transportation, warehousing, cross-docking, trucking, domestic freight, and inventory management solutions nationwide. Kerry Logistics (Phils.), Inc. (KLPI) – A joint venture with Kerry Logistics Network Limited of Hong Kong, offering domestic and international freight forwarding, warehousing, distribution, customs brokerage, project logistics, and handling of dangerous goods. 2GO Land Transport, Inc. – Provides cargo hauling and forwarding via trucks, container vans, and closed vans. 2GO Retail – Offers domestic parcel delivery, FedEx international services, and 2GO Travel ticket sales through retail outlets and partner agents. Special Container and Value Added Services, Inc. (SCVASI) – Provides cold chain and liquid bulk transport solutions, including temperature-controlled vans and ISO tanks for FCL and LCL shipments, as well as project logistics for industries such as infrastructure, power, telecommunications, mining, and property. 2GO operates passenger and freight services connecting major ports across the Philippines, linking Luzon, the Visayas, and Mindanao.
November 23, 2008: Hawaii Economists at the University of Hawaii reported that the state entered the recession in the previous quarter based on the drop in tourist figures and growing unemployment, with 8,800 jobs expected to be cut in 2009.
=== Epstein-Barr virus === The Epstein-Barr virus (EBV) infects about 90 to 95% of adults and can cause infectious mononucleosis. A study of more than 10 million US military members compared 801 people who developed MS to 1,566 matched controls who did not. The study found a 32-fold increased risk of MS development following EBV infection. It did not find an increased risk after infection with other viruses, including the similar cytomegalovirus. These findings strongly suggest that EBV is necessary for MS onset, although EBV alone may be insufficient to cause it. The nuclear antigen of EBV, which is the most consistent marker of EBV infection across all strains, has been identified as a direct source of autoreactivity in the human body. These antigens appear more likely to promote autoimmunity in vitamin D deficient persons. The EBV protein EBNA1 shares similarities with three human proteins, including the brain protein GlialCAM. Because of molecular mimicry, the immune system in MS mistakenly may attack these proteins. Two are part of the nervous system, while the third is a "guardian molecule" which protects the body against autoimmunity.
== Hadamard transform time-of-flight mass spectrometry == Hadamard transform time-of flight mass spectrometry (HT-TOFMS) is a mode of mass analysis used to significantly increase the signal-to-noise ratio of a conventional TOFMS. Whereas traditional TOFMS analyzes one packet of ions at a time, waiting for the ions to reach the detector before introducing another ion packet, HT-TOFMS can simultaneously analyze several ion packets traveling in the flight tube. The ions packets are encoded by rapidly modulating the transmission of the ion beam, so that lighter (and thus faster) ions from all initially released packets of mass from a beam get ahead of heavier (and thus slower) ions. This process creates an overlap of many time-of-flight distributions convoluted in form of signals. The Hadamard transform algorithm is then used to carry out the deconvolution process which helps to produce a faster mass spectral storage rate than traditional TOFMS and other comparable mass separation instruments.
Sources: en.wikipedia.org
The new refrigerating technology first met with widespread industrial use as a means to freeze meat supplies for transport by sea in reefer ships from the British Dominions and other countries to the British Isles. Although not actually the first to achieve successful transportation of frozen goods overseas (the Strathleven had arrived at the London docks on 2 February 1880 with a cargo of frozen beef, mutton and butter from Sydney and Melbourne), the breakthrough is often attributed to William Soltau Davidson, an entrepreneur who had emigrated to New Zealand. Davidson thought that Britain's rising population and meat demand could mitigate the slump in world wool markets that was heavily affecting New Zealand. After extensive research, he commissioned the Dunedin to be refitted with a compression refrigeration unit for meat shipment in 1881. On February 15, 1882, the Dunedin sailed for London with what was to be the first commercially successful refrigerated shipping voyage, and the foundation of the refrigerated meat industry. The Times commented "Today we have to record such a triumph over physical difficulties, as would have been incredible, even unimaginable, a very few days ago ...". The Marlborough — sister ship to the Dunedin — was immediately converted and joined the trade the following year, along with the rival New Zealand Shipping Company vessel Mataurua, while the German Steamer Marsala began carrying frozen New Zealand lamb in December 1882.
There was low- to moderate-strength evidence of no benefit for most of the other medications used in RCTs, which included antidepressants (bupropion, mirtazapine, sertraline), antipsychotics (aripiprazole), anticonvulsants (topiramate, baclofen, gabapentin), naltrexone, varenicline, citicoline, ondansetron, prometa, riluzole, atomoxetine, dextroamphetamine, and modafinil.
== Interactions == The iodine in PVP-I reacts with hydrogen peroxide, silver, taurolidine and proteins such as enzymes, rendering them (and itself) ineffective. It also reacts with many mercury compounds, giving the corrosive compound mercury iodide, as well as with many metals, making it unsuitable for disinfecting metal piercings. Iodine is absorbed into the body to various degrees, depending on application area and condition of the skin. As such, it interacts with diagnostic tests of the thyroid gland such as radioiodine diagnostics, as well as with various diagnostic agents used on the urine and stool, for example Guaiacum resin.
== Recent developments == In 2025, media reports indicated continued competition over milk quotas, with some agricultural colleges losing supplier rights under revised regulations. Later the same year, the Cabinet of Thailand approved an additional 800 million baht in emergency funds to address issues of stockpiled UHT milk and delayed deliveries.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.